National Pension Service Acquires 112,357 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

National Pension Service increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 4.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,406,013 shares of the company's stock after acquiring an additional 112,357 shares during the period. National Pension Service owned about 0.21% of Teva Pharmaceutical Industries worth $81,516,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 2.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Teva Pharmaceutical Industries by 3,376.3% in the 2nd quarter. California State Teachers Retirement System now owns 43,270,486 shares of the company's stock worth $1,466,004,000 after buying an additional 42,025,742 shares in the last quarter. WCM Investment Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the period. Finally, Norges Bank bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $1,098,060,000. Institutional investors own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on TEVA shares. Leerink Partners assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday. They issued an "outperform" rating and a $45.00 price target on the stock. Barclays lifted their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Weiss Ratings lowered shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Finally, UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a report on Friday, September 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.10.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $37.01 on Friday. The business's fifty day moving average is $34.91 and its two-hundred day moving average is $33.37. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The firm has a market cap of $43.13 billion, a P/E ratio of 61.68, a P/E/G ratio of 4.53 and a beta of 0.87. Teva Pharmaceutical Industries Ltd. has a 52 week low of $18.21 and a 52 week high of $38.37.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion during the quarter. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva's specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.